MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2024 International Congress

    Blautia argi ameliorates the motor impairment of 6-Hydroxydopamine hydrochloride-induced Parkinson’s disease rat model

    G. Tian, R. Zhou, J. Lu, W. Shi, R. Li, X. Guo (Xi'an, China)

    Objective: To evaluate the potential protective effects of Blautia argi on a 6-Hydroxydopamine (6-OHDA)-induced rat model of Parkinson's disease (PD). Background: PD is a common…
  • 2024 International Congress

    A Quantitative Investigation has Revealed Nifedipine as a Possible Pharmacological Modulator in Parkinson’s Disease

    G. Kuanar, C. Mahapatra (Cuttack, India)

    Objective: Parkinson's Disease (PD) is strongly linked to atypical electrical firing patterns in the neuronal cells of the globus pallidus externus (GPe), hence highlighting the…
  • 2024 International Congress

    Baseline Variables Associated with Apomorphine Sublingual Film Retention

    J. Kassubek, J. Schwarz, L. López Manzanares, M. Fonseca, C. Denecke Muhr (Ulm, Germany)

    Objective: The aim of this analysis was to identify the baseline variables that differ between patients who completed Study CTH-301 and those who discontinued during…
  • 2024 International Congress

    Opicapone real-world experience in early motor fluctuations: 3-months analysis of the REONPARK study.

    L. Lopez Manzanares, J. Garcia Caldentey, R. Garcia-Ramos, M. Cerdan Sanchez, B. Solano Vila, G. Castilla-Fernandez, I. Pijuan Jimenez, I. Tegel Ayuela (Madrid, Spain)

    Objective: The REONPARK study aims to evaluate COMT inhibitor (iCOMT) effectiveness and tolerability in alleviating motor complications associated with L-dopa treatment in Parkinson’s Disease patients…
  • 2024 International Congress

    One dose fits all? An analysis of the levodopa equivalent dose over time in Parkinson’s disease

    V. Lavu, J. Dwarampudi, Q. Yuan, F. Sarmento, T. de Araujo, V. Garg, J. Wong (Gainesville, USA)

    Objective: To ascertain and delineate the differences in Levodopa Equivalent Dose (LEDD) among Parkinson’s disease (PD) subtypes and to examine its evolution over the disease’s…
  • 2024 International Congress

    The impact of long-term continuous subcutaneous apomorphine infusion on the reduction of remaining medications in levodopa equivalent dosage and on increasing plasma vitamin B12 levels in patients with advanced Parkinson’s disease

    O. Phokaewvarangkul, R. Bhidayasiri (Bangkok, Thailand)

    Objective: To evaluate the plasma levels of vitamin B and homocysteine among 28 advanced PD patients with motor complications before and after continued used of…
  • 2024 International Congress

    Pathological Mechanisms Associated with Atrazine-Induced Parkinson’s Disease Pathogenesis in Rat Model: The Rescue Role of Myricetin

    C. Ikeji, E. Farombi (Ibadan, Nigeria)

    Objective: This study aimed at investigating the mechanisms involved in the pathogenesis of Parkinson’s Disease in atrazine rat model of Parkinson’s Disease and the neuroprotective…
  • 2024 International Congress

    TM9SF2 Knockdown Decreases Pathological Alpha-synuclein Aggregation In Vivo

    C. Sortwell, R. Kumaran, F. Manfredsson, C. Kemp, M. Benskey, J. Patterson, A. Stoll, J. Howe, N. Kuhn, K. Luk, M. Cookson (Grand Rapids, USA)

    Objective: To determine whether knockdown of transmembrane 9 super family 2 (TM9SF2) decreases the formation of alpha-synuclein inclusions and toxicity to nigral neurons in the…
  • 2024 International Congress

    Alpha-Synuclein and Mitochondria Quality Control in Parkinson’s Disease: A Literature Review

    L. Shen (State College, USA)

    Objective: To provide an overview of the current knowledge on alpha-synuclein (αS) interactions with mitochondrial quality control (MQC) pathways in Parkinson’s disease (PD). Background: The…
  • 2024 International Congress

    Association of Retinol Binding Protein (RBP) and the Risk of Parkinson’s disease (PD): A Narrative Literature Review

    V. Sharma (Urban, India)

    Objective: This review aimed to investigate the association between RBP levels and the risk of Parkinson’s disease Background: RBP facilitates retinol transport from the liver…
  • « Previous Page
  • 1
  • …
  • 141
  • 142
  • 143
  • 144
  • 145
  • …
  • 181
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Welcome to the MDS Abstracts Site
  • Life expectancy with and without Parkinson’s disease in the general population
  • Nilotinib for treating MSA: A preclinical proof of concept study
    • Welcome to the MDS Abstracts Site
    • Effect of marijuana on Essential Tremor: A case report
    • Advanced Search
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley